GFAP and diabetes mellitus: In response to diabetes, we observed an increase in GFAP+ immunoreactivity in the PBS-treated diabetic mice (20.34 ± 2.81) compared to their ND counterparts (7.81 ± 2.16, one-way ANOVA p < 0.01).